Have a personal or library account? Click to login
The Use of Inhaled Epoprostenol for Acute Respiratory Distress Syndrome Secondary due to COVID-19: A Case Series Cover

The Use of Inhaled Epoprostenol for Acute Respiratory Distress Syndrome Secondary due to COVID-19: A Case Series

The Journal of Critical Care Medicine
Volume 8 (2022): Issue 1 (January 2022)
By: Komal Imtiaz,  Wade Jodeh,  Dave Sudekum,  Bruno DiGiovine and  Jason Hecht  
Open Access
|Nov 2021

Authors

Komal Imtiaz

University of Texas at Houston, Houston, USA

Wade Jodeh

St Joseph Mercy Ann Arbor, Ann Arbor, USA

Dave Sudekum

St Joseph Mercy Ann Arbor, Ann Arbor, USA

Bruno DiGiovine

St Joseph Mercy Ann Arbor, Ann Arbor, USA

Jason Hecht

jason.hecht@stjoeshealth.org

St Joseph Mercy Ann Arbor, Ann Arbor, USA
DOI: https://doi.org/10.2478/jccm-2021-0037 | Journal eISSN: 2393-1817 | Journal ISSN: 2393-1809
Journal RSS Feed
Language: English
Page range: 33 - 40
Submitted on: Nov 24, 2020
|
Accepted on: Sep 27, 2021
|
Published on: Nov 17, 2021
Published by: University of Medicine, Pharmacy, Science and Technology of Targu Mures
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year
Keywords:
epoprostenol,
acute respiratory distress syndrome,
severe acute respiratory syndrome,
coronavirus
Related subjects:
Medicine,
Clinical medicine,
Internal medicine,
Internal medicine, other,
Surgery,
Surgery, other,
Anaesthesiology,
Emergency medicine and intensive-care medicine

© 2021 Komal Imtiaz, Wade Jodeh, Dave Sudekum, Bruno DiGiovine, Jason Hecht, published by University of Medicine, Pharmacy, Science and Technology of Targu Mures
This work is licensed under the Creative Commons Attribution 4.0 License.

Previous articleVolume 8 (2022): Issue 1 (January 2022)Next article